Publicly-traded company Ra Pharmaceuticals Inc. (NASDAQ:RARX) had a closing price of $46.81 yesterday. Meanwhile, the average 12-month price target from Wall Street analysts is currently $48.22, this means that the stock is underpriced by 2.92%. In the past 52 weeks the company’s stock price has moved within the range of $11.27 to $47.35.
This particular stock’s 5-day moving average is 46.88, its 20-day moving average is 44.20 and its 100-day moving average is 31.78. Ra Pharmaceuticals Inc. (RARX) currently has 47.08M shares outstanding, which means that its market capitalization is $2.20B.
The Details: Ra Pharmaceuticals Inc. (RARX) Financial Health
We can also find the company’s Return on Assets, which is a percentage that shows us how well a company uses its current assets to make a profit. The larger the score, the better. At the moment, Ra Pharmaceuticals Inc. Return on Assets is -41.80%.
What Does Wall Street Say about Company?
When considering a stock buy, many investors seek to know what Wall Street analysts are saying about the company – by looking at the average analyst rating, for example. At the moment, the average analyst rating for RARX is Overweight. Out of 10 total analysts who were surveyed, 0 rated it a sell, 0 rated it a underweight, 0 rated it an overweight, 7 rated it hold, and 3 rated it a Buy.
Three months ago, on the other hand, the average analyst rating for Ra Pharmaceuticals Inc. (RARX) was a Buy – from a survey of 10 analysts. Of the analysts who provided ratings, 1 rated the company a Hold, 0 rated it a Sell, 1 rated it an overweight, 0 rated it an underweight, and 8 rated it a Buy.
Understanding Profitability at Ra Pharmaceuticals Inc. (RARX)
A smart way of assessing a company’s profitability is by checking out its latest Earnings per Share (EPS). In the most recent financial results released by Ra Pharmaceuticals Inc., for the quarter ending on 09/2019, the company posted EPS of -0.50. The average estimate of Wall Street analysts had projected -0.44.
Wall Street analysts, on average, are forecasting the company’s EPS to be -0.50, compared to -0.51 reported in the same quarter last year. When it comes to net revenue, the average estimate from a total of 8 analysts is 750k.